← All trials
NCT06205628
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 21, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Sep 30, 2026
- First posted
- Jan 16, 2024
- Last posted
- Nov 12, 2024
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ADARx Pharmaceuticals, Inc.Lead sponsor
- Avance Clinical Pty Ltd.Collaborator
- ADARx Pharmaceuticals, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.